enGene Therapeutics Inc. (ENGN)

Nasdaq: ENGN · Biological Products, (No Diagnostic Substances) · Saint-Laurent, QC · filing with the SEC since 2023

Full chart Alerts Compare

Grade4.3

◀ Past 4.1● Present 3.8▶ Future 4.8

6 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

Who owns enGene Therapeutics Inc.

As filed with the SEC

Holders of 5% or more

Perceptive Advisors LLC holds 9.99% of Common Shares, as its SCHEDULE 13G/A filed Aug 14, 2026 says.

Directors and officers

report now, of 26 people on the record since 2023. Their holdings as a group are not read here.

Institutions as a whole

n/a

The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.

Holders of 5% or moreshare of the class, as filed

Perceptive Advisors LLC

SCHEDULE 13G/A · filed Aug 14, 2026 · Common Shares · 9.99% in Nov 18, 2025

9.99%

BML Investment Partners, L.P.

SCHEDULE 13G/A · filed May 14, 2026 · Common Shares · 7.8% in May 13, 2026

9.95%

Raymond Debbane

SCHEDULE 13G/A · filed Aug 13, 2026 · Common Shares · 7.8% in May 5, 2026

9.3%

Anders Hove

SCHEDULE 13G · filed Jul 22, 2026 · Common Shares

Fonds de solidarite des travailleurs et des travailleuses du Quebec

SCHEDULE 13G/A · filed Oct 21, 2024 · Common Shares · reported falling below 5%

under 5%

Adage Capital Management, L.P.

SCHEDULE 13G/A · filed Feb 12, 2025 · Common Shares, with no par value per share · reported falling below 5%

under 5%

Kynam Capital Management, LP

SCHEDULE 13G/A · filed Feb 17, 2026 · Common Shares, no par value per share · reported falling below 5%, from 9.8% in Feb 14, 2025

under 5%

Bvf Partners L P/il

SCHEDULE 13G/A · filed Jan 29, 2025 · Common Shares, no par value per share · reported falling below 5%, from 5.9% in Jan 29, 2025

under 5%

Blue Owl Capital Holdings LP

SCHEDULE 13G/A · filed Aug 12, 2026 · Common Shares, no par value · reported falling below 5%

under 5%

Venrock Healthcare Capital Partners III, L.P.

SCHEDULE 13G/A · filed Aug 14, 2026 · Common Shares · reported falling below 5%, from 7.1% in Feb 17, 2026

under 5%

Deep Track Capital, LP

SCHEDULE 13G/A · filed Aug 14, 2026 · Common Shares · reported falling below 5%, from 6.69% in Nov 18, 2025

under 5%

Cormorant Asset Management, LP

SCHEDULE 13G/A · filed May 15, 2026 · Common Shares · reported falling below 5%, from 5.97% in Feb 17, 2026

under 5%

Foresite Capital Fund VI, L.P.

SCHEDULE 13G/A · filed Feb 14, 2025 · Common Shares, no par value · reported falling below 5%

under 5%

What ENGN reports owning in othersstakes of 5% or more, and other ties

enGene Therapeutics Inc. reports no stake in another company in the record.

Insider tradesForm 4

0sales

1purchases

0sales on a scheduled plan

0people selling

$0sold, in dollars

$0bought, in dollars

Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.

By calendar yearSoldBought

2426

2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.

People who traded in the window1 of 43 on the roster

Person	Role as filed	Sales	Sold	On a plan	Buys	Bought
Grossman William	Interim Chief Medical Officer	0	$0	0	1	$0

SI Assistanton ENGN · research, not advice